Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study

Lydia P Howell, S. J. DeNardo, N. B. Levy, J. Lund, Gerald L Denardo

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Five monoclonal antibodies (MoAbs) (L6, 170H.82, 155, BrE-3 and BR96), most of which have been previously shown to target breast cancer and not normal tissues by immunoscintigraphic imaging, were evaluated for their frequency and pattern of immunohistochemical staining in 67 to 116 metastatic lesions from patients with ductal carcinoma of the breast. Immunoperoxidase staining in 75% or more of the cells occurred in 56/116 (48%) for L6, 44/89 (49%) for Br, -96, 58/102 (57%) for 155, 62/99 (84%) for 170H.82, and 65.67 (97%) for BrE-3. With the first three MoAbs, an additional 6-10% of the tumors showed staining in 50-75% of tumor cells. These results illustrate that most patients with metastatic ductal carcinoma have cancer tissue in which a high percent of cells will react to several of these selected MoAbs that target different epitopes. The high expression of the MoAb targets throughout the tumor tissue makes these antibodies potential candidates to carry immunologically directed radioimmunotherapy and is an aid in selecting patients for treatment.

Original languageEnglish (US)
Pages (from-to)129-135
Number of pages7
JournalInternational Journal of Biological Markers
Volume10
Issue number3
StatePublished - 1995

Fingerprint

Carcinoma, Ductal, Breast
Tumors
Monoclonal Antibodies
Tissue
Staining and Labeling
Imaging techniques
Neoplasms
Radioimmunotherapy
Ductal Carcinoma
Epitopes
Therapeutics
Cells
Antibodies
Breast Neoplasms

Keywords

  • Breast cancer
  • Immunopathology
  • Monoclonal antibodies
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Biochemistry
  • Immunology

Cite this

@article{6c1e0dd8a938411b989881c05ee2ec89,
title = "Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study",
abstract = "Five monoclonal antibodies (MoAbs) (L6, 170H.82, 155, BrE-3 and BR96), most of which have been previously shown to target breast cancer and not normal tissues by immunoscintigraphic imaging, were evaluated for their frequency and pattern of immunohistochemical staining in 67 to 116 metastatic lesions from patients with ductal carcinoma of the breast. Immunoperoxidase staining in 75{\%} or more of the cells occurred in 56/116 (48{\%}) for L6, 44/89 (49{\%}) for Br, -96, 58/102 (57{\%}) for 155, 62/99 (84{\%}) for 170H.82, and 65.67 (97{\%}) for BrE-3. With the first three MoAbs, an additional 6-10{\%} of the tumors showed staining in 50-75{\%} of tumor cells. These results illustrate that most patients with metastatic ductal carcinoma have cancer tissue in which a high percent of cells will react to several of these selected MoAbs that target different epitopes. The high expression of the MoAb targets throughout the tumor tissue makes these antibodies potential candidates to carry immunologically directed radioimmunotherapy and is an aid in selecting patients for treatment.",
keywords = "Breast cancer, Immunopathology, Monoclonal antibodies, Radioimmunotherapy",
author = "Howell, {Lydia P} and DeNardo, {S. J.} and Levy, {N. B.} and J. Lund and Denardo, {Gerald L}",
year = "1995",
language = "English (US)",
volume = "10",
pages = "129--135",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing",
number = "3",

}

TY - JOUR

T1 - Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy

T2 - A comparative study

AU - Howell, Lydia P

AU - DeNardo, S. J.

AU - Levy, N. B.

AU - Lund, J.

AU - Denardo, Gerald L

PY - 1995

Y1 - 1995

N2 - Five monoclonal antibodies (MoAbs) (L6, 170H.82, 155, BrE-3 and BR96), most of which have been previously shown to target breast cancer and not normal tissues by immunoscintigraphic imaging, were evaluated for their frequency and pattern of immunohistochemical staining in 67 to 116 metastatic lesions from patients with ductal carcinoma of the breast. Immunoperoxidase staining in 75% or more of the cells occurred in 56/116 (48%) for L6, 44/89 (49%) for Br, -96, 58/102 (57%) for 155, 62/99 (84%) for 170H.82, and 65.67 (97%) for BrE-3. With the first three MoAbs, an additional 6-10% of the tumors showed staining in 50-75% of tumor cells. These results illustrate that most patients with metastatic ductal carcinoma have cancer tissue in which a high percent of cells will react to several of these selected MoAbs that target different epitopes. The high expression of the MoAb targets throughout the tumor tissue makes these antibodies potential candidates to carry immunologically directed radioimmunotherapy and is an aid in selecting patients for treatment.

AB - Five monoclonal antibodies (MoAbs) (L6, 170H.82, 155, BrE-3 and BR96), most of which have been previously shown to target breast cancer and not normal tissues by immunoscintigraphic imaging, were evaluated for their frequency and pattern of immunohistochemical staining in 67 to 116 metastatic lesions from patients with ductal carcinoma of the breast. Immunoperoxidase staining in 75% or more of the cells occurred in 56/116 (48%) for L6, 44/89 (49%) for Br, -96, 58/102 (57%) for 155, 62/99 (84%) for 170H.82, and 65.67 (97%) for BrE-3. With the first three MoAbs, an additional 6-10% of the tumors showed staining in 50-75% of tumor cells. These results illustrate that most patients with metastatic ductal carcinoma have cancer tissue in which a high percent of cells will react to several of these selected MoAbs that target different epitopes. The high expression of the MoAb targets throughout the tumor tissue makes these antibodies potential candidates to carry immunologically directed radioimmunotherapy and is an aid in selecting patients for treatment.

KW - Breast cancer

KW - Immunopathology

KW - Monoclonal antibodies

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029064825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029064825&partnerID=8YFLogxK

M3 - Article

C2 - 8551054

AN - SCOPUS:0029064825

VL - 10

SP - 129

EP - 135

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 3

ER -